Mounjaro (approved May 2022) is indicated for blood sugar management in Type 2 diabetes
Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini W
Patients receiving semaglutide in the STEP trials experienced significant fat loss without glutathione supplementation, indicating that glutathione addition is unlikely to enhance the primary weight loss mechanism
Biallelic mutations in ARMC12 cause asthenozoospermia and multiple midpiece defects in humans and mice
Again however, there is little evidence that these compounds would provide therapeutic benefits with conditions related to XO-derived RS production
The medication is approved for type 2 diabetes management (as Ozempic) and weight management in people with obesity (as Wegovy)